ZHANG Guo-chun. Cisplatin Plus Gemcitabine Can Be Applied as First-Line or even Preferred Regimen in Metastatic Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 65-65. DOI: 10.3969/j.issn.1671-5144.2015.02.001
|
Citation:
|
ZHANG Guo-chun. Cisplatin Plus Gemcitabine Can Be Applied as First-Line or even Preferred Regimen in Metastatic Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 65-65. DOI: 10.3969/j.issn.1671-5144.2015.02.001
|
ZHANG Guo-chun. Cisplatin Plus Gemcitabine Can Be Applied as First-Line or even Preferred Regimen in Metastatic Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 65-65. DOI: 10.3969/j.issn.1671-5144.2015.02.001
|
Citation:
|
ZHANG Guo-chun. Cisplatin Plus Gemcitabine Can Be Applied as First-Line or even Preferred Regimen in Metastatic Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 65-65. DOI: 10.3969/j.issn.1671-5144.2015.02.001
|
DownLoad: